CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

This summary highlights global health-related news, including the WHO's approval of a vaccine for adolescents, France seeking ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New ...

Novo Holdings is set to buy one less facility from Catalent as the manufacturer has sold a facility in New Jersey to a ...